{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:49:45Z","timestamp":1790894985141,"version":"4.1.0"},"reference-count":25,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Stroke"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The CHANCE-2 study compared 3\u2009weeks of aspirin\u2013ticagrelor to aspirin\u2013clopidogrel in CYP2C19 loss-of-function (LOF) allele carriers following a transient ischemic attack (TIA)\/minor stroke and demonstrated a modestly lower risk of stroke recurrence with aspirin\u2013ticagrelor. This stroke protection was largely for minor stroke and came at an increased risk of bleeding. The cost-effectiveness of implementing testing for LOF allele status to personalize antiplatelet regimen for secondary stroke prevention after a TIA\/minor stroke in the Canadian health care context is unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Cost-effectiveness analysis using a decision-analytic Markov cohort model with a lifetime horizon was performed to determine the costs and health benefits of testing for LOF allele status compared with no testing (current standard of care). The population of interest was patients living in Canada who suffered a TIA\/minor stroke. Outcomes of interest were life-years gained (LYG), quality-adjusted life years (QALY) gained, costs (reported in 2022 Canadian dollars), and the incremental cost-effectiveness ratio (ICER). We adopted the perspective of the Federal, Provincial, and Territorial Ministries of Health and used a 1.5% annual discount rate. Sensitivity analyses were performed to assess uncertainty.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Compared to standard of care, LOF allele testing leads to 0.14 LYG (undiscounted), 0.12 QALYs gained (undiscounted), and additional lifetime costs of CAD$432 (discounted) per patient. The ICER of the LOF allele testing strategy is CAD$4310 per QALY gained compared with standard of care. The probabilistic sensitivity analyses demonstrated that LOF allele testing was cost-effective in more than 99.99% of simulations using a willingness-to-pay threshold of CAD$50,000 per QALY.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Based on available evidence, testing for LOF allele followed by short duration 3\u2009weeks of aspirin\u2013ticagrelor compared to standard-of-care aspirin\u2013clopidogrel can lead to prolonged life and improved quality of life and can be considered very cost-effective when compared with other well-accepted technologies in health and medicine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17474930221111898","type":"journal-article","created":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T00:30:12Z","timestamp":1656030612000},"page":"416-425","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":16,"title":["Cost-effectiveness of testing for CYP2C19 loss-of-function carriers following transient ischemic attack\/minor stroke: A Canadian perspective"],"prefix":"10.1177","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6393-5001","authenticated-orcid":false,"given":"Andrew","family":"Micieli","sequence":"first","affiliation":[{"name":"Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishita","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Jahn","sequence":"additional","affiliation":[{"name":"Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT \u2014University for Health Sciences, Medical Informatics and Technology, Hall in Tirol, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Siebert","sequence":"additional","affiliation":[{"name":"Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT \u2014University for Health Sciences, Medical Informatics and Technology, Hall in Tirol, Austria"},{"name":"Program on Cardiovascular Research, Institute for Technology Assessment and Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA"},{"name":"Center for Health Decision Science, Departments of Epidemiology and Health Policy & Management, Harvard T.H. Chan School of Public Health, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijoy K","family":"Menon","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M","family":"Demchuk","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,8,24]]},"reference":[{"key":"bibr1-17474930221111898","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000129482.70315.2F"},{"key":"bibr2-17474930221111898","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.22.2901"},{"key":"bibr3-17474930221111898","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215340"},{"key":"bibr4-17474930221111898","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.2531"},{"key":"bibr5-17474930221111898","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800410"},{"key":"bibr6-17474930221111898","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000074"},{"key":"bibr7-17474930221111898","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.119.007811"},{"key":"bibr8-17474930221111898","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.8662"},{"key":"bibr9-17474930221111898","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1008410"},{"key":"bibr10-17474930221111898","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l2211"},{"key":"bibr11-17474930221111898","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2111749"},{"key":"bibr12-17474930221111898","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1405158"},{"key":"bibr13-17474930221111898","unstructured":"Guidelines for the Economic Evaluation of Health Technologies: Canada. 4th ed. https:\/\/www.cadth.ca\/sites\/default\/files\/pdf\/guidelines_for_the_economic_evaluation_of_health_technologies_canada_4th_ed.pdf"},{"key":"bibr14-17474930221111898","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.024913"},{"key":"bibr15-17474930221111898","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq250"},{"key":"bibr16-17474930221111898","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12454577"},{"key":"bibr17-17474930221111898","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.02.010"},{"key":"bibr18-17474930221111898","unstructured":"Government of Canada SC. Life tables, Canada, provinces and territories. https:\/\/www150.statcan.gc.ca\/n1\/en\/catalogue\/84-537-X (2022, accessed 15 February 2022)."},{"key":"bibr19-17474930221111898","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.000912"},{"key":"bibr20-17474930221111898","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-200006000-00004"},{"key":"bibr21-17474930221111898","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.120.031108"},{"key":"bibr22-17474930221111898","unstructured":"NICE. Spartan RX and point-of-care CYP2C19 test to guide treatment in acute coronary syndrome. https:\/\/www.nice.org.uk\/advice\/mib223\/resources\/spartan-rx-pointofcare-cyp2c19-test-to-guide-treatment-in-acute-coronary-syndrome-pdf-2285965510334917"},{"key":"bibr23-17474930221111898","unstructured":"Pricing. Pharmaceutic pricing. https:\/\/pricingdoc.acfp.ca\/pricing\/ (accessed 22 December 2021)."},{"key":"bibr24-17474930221111898","unstructured":"CIHI. Patient Cost Estimator. https:\/\/www.cihi.ca\/en\/patient-cost-estimator (accessed 19 December 2021)."},{"key":"bibr25-17474930221111898","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.121.034089"}],"container-title":["International Journal of Stroke"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17474930221111898","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17474930221111898","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17474930221111898","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T07:21:12Z","timestamp":1777706472000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17474930221111898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,24]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.1177\/17474930221111898"],"URL":"https:\/\/doi.org\/10.1177\/17474930221111898","relation":{},"ISSN":["1747-4930","1747-4949"],"issn-type":[{"value":"1747-4930","type":"print"},{"value":"1747-4949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,24]]}}}